Olodaterol, a once-daily, long-acting beta2-agonist (LABA), has recently been regulatory approved overseas with indication of chronic obstructive pulmonary disease (COPD). It has the pharmacological features of high intrinsic activity in addition to selectivity and affinity for the beta2-adrenergic receptor. Various phaseIII clinical trials have shown the high effectiveness of olodaterol in patients with COPD, as well as its excellent clinical benefits including safety comparable to that of placebo. Olodaterol was developed as an inhalation medication to be administered by Respimat. In Japan, future therapeutic contribution of olodaterol is expected mostly in combination with tiotropium, whose clinical benefit has already been established in the treatment of COPD.
|Number of pages||17|
|Journal||Japanese Pharmacology and Therapeutics|
|Publication status||Published - 2015|
- Chronic obstructive pulmonary disease (COPD)
- Long-acting beta2-agonist (LABA)
ASJC Scopus subject areas
- Pharmacology (medical)